NYSE:IQV IQVIA (IQV) Stock Price, News & Analysis $157.52 -0.64 (-0.40%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$157.48 -0.05 (-0.03%) As of 06/27/2025 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About IQVIA Stock (NYSE:IQV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IQVIA alerts:Sign Up Key Stats Today's Range$156.01▼$159.5850-Day Range$136.96▼$159.7052-Week Range$134.65▼$252.88Volume2.31 million shsAverage Volume1.64 million shsMarket Capitalization$27.25 billionP/E Ratio21.46Dividend YieldN/APrice Target$226.32Consensus RatingModerate Buy Company OverviewIQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.Read More… IQVIA Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreIQV MarketRank™: IQVIA scored higher than 98% of companies evaluated by MarketBeat, and ranked 25th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingIQVIA has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 16 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageIQVIA has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about IQVIA's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth12.55% Earnings GrowthEarnings for IQVIA are expected to grow by 12.55% in the coming year, from $10.84 to $12.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IQVIA is 21.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.00.Price to Earnings Ratio vs. SectorThe P/E ratio of IQVIA is 21.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.15.Price to Earnings Growth RatioIQVIA has a PEG Ratio of 1.75. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIQVIA has a P/B Ratio of 4.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about IQVIA's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.44% of the float of IQVIA has been sold short.Short Interest Ratio / Days to CoverIQVIA has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IQVIA has recently increased by 29.58%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIQVIA does not currently pay a dividend.Dividend GrowthIQVIA does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.69 Percentage of Shares Shorted5.44% of the float of IQVIA has been sold short.Short Interest Ratio / Days to CoverIQVIA has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IQVIA has recently increased by 29.58%, indicating that investor sentiment is decreasing significantly. News and Social Media3.4 / 5News Sentiment1.19 News SentimentIQVIA has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for IQVIA this week, compared to 18 articles on an average week.Search Interest11 people have searched for IQV on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added IQVIA to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, IQVIA insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.60% of the stock of IQVIA is held by insiders.Percentage Held by Institutions89.62% of the stock of IQVIA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IQVIA's insider trading history. Receive IQV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter. Email Address IQV Stock News HeadlinesIQV - IQVIA Holdings Inc Sustainability | MorningstarJune 28 at 11:06 AM | morningstar.comMIQV - IQVIA Holdings Inc Valuation | MorningstarJune 28 at 11:06 AM | morningstar.comMTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move. | Porter & Company (Ad)The Top 5 Analyst Questions From IQVIA’s Q1 Earnings CallJune 27 at 3:53 AM | finance.yahoo.comIQV - IQVIA Holdings Inc Trailing Returns | MorningstarJune 26, 2025 | morningstar.comMDrug Development Inputs & Services Stocks Q1 Highlights: IQVIA (NYSE:IQV)June 17, 2025 | msn.comAccelerating Clinical Research and Commercialization with AI AgentsJune 16, 2025 | msn.comIQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for 'Best Mobile App for Patient Engagement'June 16, 2025 | tmcnet.comSee More Headlines IQV Stock Analysis - Frequently Asked Questions How have IQV shares performed this year? IQVIA's stock was trading at $196.51 at the beginning of the year. Since then, IQV stock has decreased by 19.8% and is now trading at $157.5250. View the best growth stocks for 2025 here. How were IQVIA's earnings last quarter? IQVIA Holdings Inc. (NYSE:IQV) posted its quarterly earnings results on Tuesday, May, 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA's quarterly revenue was up 2.5% on a year-over-year basis. Read the conference call transcript. Does IQVIA have any subsidiaries? The following companies are subsidiaries of IQVIA: Q2 Solutions, Linguamatics, Advanced Health Media LLC, DrugDev, Aileron Solutions, Novella Clinical LLC, 159 Solutions LLC, and others. Who are IQVIA's major shareholders? Top institutional investors of IQVIA include Vanguard Group Inc. (11.47%), Canada Pension Plan Investment Board (2.66%), Alliancebernstein L.P. (2.04%) and JPMorgan Chase & Co. (1.47%). Insiders that own company stock include Ari Bousbib, Eric Sherbet, Constantinos Panagos, Kevin C Knightly and John G Danhakl. View institutional ownership trends. How do I buy shares of IQVIA? Shares of IQV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IQVIA own? Based on aggregate information from My MarketBeat watchlists, some other companies that IQVIA investors own include NVIDIA (NVDA), Chevron (CVX), Meta Platforms (META), Bristol Myers Squibb (BMY), Advanced Micro Devices (AMD), Broadcom (AVGO) and McKesson (MCK). Company Calendar Last Earnings5/06/2025Today6/29/2025Next Earnings (Estimated)7/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED INSTRUMENTS Sub-IndustryBusiness Services Current SymbolNYSE:IQV CIK1478242 Webwww.iqvia.com Phone(919) 998-2000FaxN/AEmployees88,000Year Founded2016Price Target and Rating Average Stock Price Target$226.32 High Stock Price Target$276.00 Low Stock Price Target$160.00 Potential Upside/Downside+43.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)$7.34 Trailing P/E Ratio21.46 Forward P/E Ratio14.53 P/E Growth1.75Net Income$1.37 billion Net Margins8.61% Pretax Margin10.66% Return on Equity29.16% Return on Assets6.96% Debt Debt-to-Equity Ratio2.19 Current Ratio0.82 Quick Ratio0.82 Sales & Book Value Annual Sales$15.41 billion Price / Sales1.77 Cash Flow$16.62 per share Price / Cash Flow9.48 Book Value$33.43 per share Price / Book4.71Miscellaneous Outstanding Shares173,000,000Free Float170,232,000Market Cap$27.25 billion OptionableOptionable Beta1.28 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NYSE:IQV) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored“Trump’s 24-Hour Profit Windows” revealedTrading legend Larry Benedict has discovered a repeating surge of $240 billion (and more)... Flowing into a...Brownstone Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IQVIA Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IQVIA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.